Counseling sexually active teenagers treated with potential human teratogens

Journal of Adolescent Health

Volumn 21, Issue 3, 1997, Pages 143-146

  Shilalukey, Kathleen ^a,c   Kaufman, Miriam ^a,c   Bradley, Susan ^a,c   Francombe, William H ^a,c   Amankwah, Koffi ^a,c   Goldberg, Eudice ^a,c   Shear, Neil ^a,c   Olivieri, Nancy F ^a,c   Koren, Gideon ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Adolescents; Counseling; Iron chelators; Teratogens

Indexed keywords

CHELATING AGENT; DEFERIPRONE; DEFEROXAMINE; GONADORELIN; ORAL CONTRACEPTIVE AGENT; SPERMICIDAL AGENT; TERATOGENIC AGENT;

ADOLESCENT; ADULT; ARTICLE; BLOOD TRANSFUSION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONDOM; CONTRACEPTION; FEMALE; HEMOGLOBINOPATHY; HUMAN; IRON CHELATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PATIENT COUNSELING; PRACTICE GUIDELINE; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; SEXUAL BEHAVIOR; SICKLE CELL ANEMIA; THALASSEMIA MAJOR;

ADOLESCENT; ADOLESCENT BEHAVIOR; ANEMIA, SICKLE CELL; BETA-THALASSEMIA; CONTRACEPTION BEHAVIOR; COUNSELING; DEFEROXAMINE; FEMALE; FERTILITY; HUMANS; IRON CHELATING AGENTS; PREGNANCY; PYRIDONES; SEX EDUCATION; SEXUAL BEHAVIOR; TERATOGENS;

EID: 0030858454     PISSN: 1054139X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1054-139X(97)00041-4     Document Type: Article

References (18)

1. Newman CGH. Teratogen update: Clinical aspects of thalidomide embryopathy - a continuing preoccupation. Teratology 1985;32:133-44.
2. Koren G, Nulman I. Teratogenic drugs and chemicals in humans. In: Maternal-Fetal Toxicology, 2nd ed. Koren G, ed. New York: Marcel Dekker, 1994, pp. 33-48.
3. Pastuszak A, Koren G. The retinoids of pregnancy prevention program. In: Retinoids in Clinical Practice. The Risk-Benefit Ratio. Koren G, ed. New York: Marcel Dekker, 1993, pp. 147-75.
4. Koren G. Retinoic acid embryopathy. N Engl J Med 1986;315:262.
5. Bronspiegel-Weintrob N, Olivieri NF, Tyler B, et al. Effect of age at the start of iron chelation therapy on gonadal function in β-thalassemia major. N Engl J Med 1990;323:713-9.
6. Ciba Pharmaceutical Company. Official literature on new drugs deferoxamine mesylate: A specific iron-chelating agent for treating acute iron intoxication. Clin Pharmacol Ther 1967;10:595-6.
7. Ciba-Geigy Report on Desferal to the FDA, 1966.
8. Thomas RM, Skalioka AE. Successful pregnancy in transfusion dependent thalassemia. Arch Dis Child 1980;55:572-4.
9. Martin K. Successful pregnancy in β-thalassemia major. Aust Fed J 1983;19:182-3.
10. Dolfin G, Lumare A, Tinetti E, et al. Problemi ostetrici ed etamologici in una gestante affetta da beta-thalassemia intemedia. Min Gin 1983;35:227-30.
11. Kyriakou D, Papanicolaou C, Gyparaki M, et al. Absence of desferrioxamine teratogenicity in a thalassemic patient. Second International Conference on Thalassemia and the Haemoglobinopathies. Herakleion (Crete) Greece. Oct. 21-24, 1987. Abstract p. 109.
12. McElhatton PR, Roberts JC, Sullivan FM. The consequences of iron overdose and its treatment with desferrioxamine in pregnancy. Hum Exp Toxicol 1991;10:251-9.
13. Turk J, Arks S, Hryhorczuk DO. Successful therapy of iron intoxication in pregnancy with intravenous deferoxamine and whole bowel irrigation. Vet Hum Toxicol 1993;35:441-4.
14. Ciba-Geigy final report: Preclinical evaluation of CG P 37 391 (L1): 1993. Schnebli HP, ed. Biology Report ERS 62/93, p. 19.
15. Olivieri NF, Koren G, Harris J, et al. Growth failure and bony changes induced by deferoxamine. Am J Ped Hem Oncol 1992;14:48-56.
16. Planeczky M, Slap G, Forke C, et al. The use of levonorgestrel implant (Norplant) for contraception in adolescent mothers. N Engl J Med 1994;331:1201-6.
17. Schlossberger N. Validity of self-report of pubertal maturation in early adolescents. J Adolesc Health 1992;13:109-13.
18. Kaufman M. Easy for You to Say. Key-Porter Books, 1995.